According to GlobalData’s medical device pipeline database, 13 Acellular Skin Substitutes devices are in various stages of development globally. GlobalData’s report Acellular Skin Substitutes provides an overview of the segment’s pipeline landscape and offers detailed analysis of its products. Buy the report here.
Of these devices, two are in active development, while the remaining 11 are in an inactive stage of development. There are one products in the early stages of development, and the remaining one is in the late stages of development.
Wound care management market comprises of dressings, equipment and other aids to prevent, treat wounds and also quicken or promote wound healing. Acellular skin substitutes are bioengineered skin products that are made from the processed extracellular matrix of human or animal skin. The extracellular matrix is the non-cellular part of the skin that provides support and structure to the cells. Acellular skin substitutes are used to treat chronic wounds that have not healed with standard wound care. They work by providing a scaffold for the body’s own cells to grow and heal the wound.
Innovations in the medical devices sector are linked to the development of new approaches, processes, or technologies for treating, diagnosing, and managing disease in response to demand from healthcare for better patient outcomes and reduce healthcare costs.
Based on an analysis of GlobalData’s Medical Intelligence Center pipeline product database, these actively developed Acellular Skin Substitutes pipeline devices are all expected to be approved within the next ten years.
Currently, private organizations, public entities and institutions are working on the development of Acellular Skin Substitutes devices. Overall, most of these Acellular Skin Substitutes pipeline devices are being developed by private entities.
Key players involved in the active development of Acellular Skin Substitutes include Acro Biomedical, Tissue Regenix Group, China Regenerative Medicine International, Kerecis ehf, LifeCell, Osiris Therapeutics and XenoTherapeutics.
For a complete picture of the developmental pipeline for Acellular Skin Substitutes devices, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.